Article

Multi-omics data integration reveals molecular mechanisms of carfilzomib resistance in multiple myeloma

2024-05-31

Abstract excerpt

Multiple myeloma represents a complex hematological malignancy, characterized by its wide array of genetic and clinical events. The introduction of proteasome inhibitors, such as carfilzomib or bortezomib, into the therapeutic landscape has notably enhanced the quality of life and survival rates for patients suffering from this disease. Nonetheless, a significant obstacle in the long-term efficacy of this treatmen...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: bbd42235-37c6-52e2-9ca2-ec21ef02a20c
DOI: 10.1101/2024.05.26.595929

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Multi-omics data integration reveals molecular mechanisms of carfilzomib resistance in multiple myelomaDOI 10.1101/2024.05.26.595929Read

The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myelomaSemantic proximity Read

Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myelomaSemantic proximity Read

Advancements in Multiple Myeloma Research: High-Throughput Sequencing Technologies, Omics, and the Role of Artificial IntelligenceSemantic proximity Read

Different Strategies to Overcome Resistance to Proteasome Inhibitors—A Summary 20 Years after Their IntroductionSemantic proximity Read

Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities.Semantic proximity Read

Molecular mechanisms in multiple myeloma drug resistance.Semantic proximity Read

Multi-omics advances for molecular characterization, precision medicine, and prognostic implications in leukemiaSemantic proximity Read

IMiD Resistance in Multiple Myeloma: Current Understanding of the Underpinning Biology and Clinical ImpactSemantic proximity Read

The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple MyelomaSemantic proximity Read

Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myelomaSemantic proximity Read

Integrative multi-omics identifies high risk multiple myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathwaysSemantic proximity Read

Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanismsSemantic proximity Read